BC Catalyst brings AI‑native analytics to life sciences, turning real‑world and genomic data into fast, trustworthy insights that help teams advance drug development and improve decision‑making. In this FAQ, chief product officer Keith Collier explains how the platform is reshaping decision‑making and accelerating development.
Q: What challenges does BC Catalyst address?
Keith: Life sciences organizations are dealing with a tough environment. There’s constant pressure to deliver new therapies faster and at lower cost. Yet market entry success rates are typically as low as 10%, and development timelines often span 10-15 years1 and cost an average of more than $2.6 billion per new therapy2. A big part of the problem is the sheer volume of fragmented, incomplete, and siloed data — everything from structured and unstructured genomics and real-world clinical information — that slows down innovation and critical decision-making. Teams often spend weeks or months just gathering and cleaning data before they can even start answering basic questions. It’s been a problem for years.
Q: How does BC Catalyst overcome these challenges?
Keith:BC Catalyst overcomes these challenges by helping companies make better decisions – faster – using an innovative, AI-native platform that’s supported by harmonized multi-modal real-world and genomics data. It uses prompt-based queries that quickly surface insights, from patient trends to how treatments are performing in the market.
This helps life sciences companies design more personalized and precise medicines, and supports them throughout discovery, clinical trial planning, development, and commercial decision-making. It’s a huge step forward for how teams can use data.
Q: What does BC Catalyst mean for the life sciences industry?
Keith: BC Catalyst makes it much easier, and faster, to query and analyze vast volumes of data that’s already been integrated and harmonized. And this is done all within an intuitive, prompt-based interface. It streamlines a lot of the heavy lifting so teams can focus on the science rather than the data wrangling. When researchers can see treatment patterns, patient responses, biomarker signals, and evolving standards of care in minutes, they can make decisions that were simply not feasible before. Customers can use BC Catalyst via prompt-based and exploration, built-in AI agents and preconfigured evidence streams. The platform’s backend algorithms take a clinical or scientific question and instantly assemble a coherent, evidence-backed view of the patient population.
Customers can use BC Catalyst via prompt-based and exploration, built-in AI agents and preconfigured evidence streams.
By combining real-world multimodal data with automated literature synthesis, BC Catalyst compresses weeks of chart reviews, data pulls, and manual research into a single prompt. This gives users immediate visibility into treatment patterns, patient responses, biomarker signals, and standards of care in one integrated view. That means discovering new therapeutic opportunities earlier, designing smarter trials, identifying the right patients with far greater precision, and targeting existing therapies to the populations most likely to benefit.
BC Catalyst removes the friction that has slowed evidence generation for years. That’s a huge impact.
Q: How does BC Catalyst reflect real-world needs?
Keith: BC Catalyst was built with direct input from clinicians, researchers and other key players across the life sciences ecosystem, so it’s stays aligned with what people need in their day-to-day projects and tasks. Clinicians help to define the questions that matter most and can see how treatments affect outcomes across different patient groups. Researchers can look at the same data to generate insights that support clinical trials and studies.
With agentic AI-driven queries and clear visualizations, BC Catalyst helps translate complex data into insights that are easier to understand, making it quicker to reach evidence-based decisions.
Q: Who can benefit from using BC Catalyst?
Keith: BC Catalyst is useful for a wide range of life sciences organizations— from startups and biotechs to mid-sized and global pharma. It’s meant for R&D, medical affairs, clinical and commercial teams that need quick, reliable insights. Who doesn’t want to move faster?
The platform cuts down the time and effort required to access and analyze real-world and genomic data, along with public datasets. Tasks that used to take weeks of gathering, cleaning and building custom analyses can now be done in seconds. And since BC Catalyst is prompt-based, users don’t need to be data scientists or technical experts. They can work with trusted data through a simple interface and easily generate actionable insights.
Q: How is data harmonized for use with BC Catalyst?
Keith: The data that BC Catalyst applies is powered by BC Unify, our AI-driven data mastering platform. It anonymizes, enriches, harmonizes and integrates data so it’s ready for predictive analytics and other activities. That harmonized data is then made available and visualized through BC Catalyst.
Q: What about patient privacy and related data governance standards?
Keith: At BC Platforms, we’ve spent more than 25 years working with trusted research environments and handling sensitive healthcare data, so privacy is something we understand very well – and take very seriously. Our infrastructure and processes meet stringent standards for data governance, privacy and security. Customers can have peace of mind that they’re working in an environment that meets data compliance requirements.
Q: What is agentic AI?
Keith: Agentic AI goes beyond answering questions. It autonomously plans, executes, and adapts to accomplish research goals. Unlike traditional AI that responds to individual prompts, agentic AI breaks down objectives into steps, uses multiple tools and data sources, and makes intelligent decisions to deliver comprehensive insights with minimal human intervention. Examples of usage include:
Multi-Step hypothesis testing: BC Catalyst autonomously designs and executes research workflows. Ask a single question, and the system identifies relevant patient cohorts, and cross-references findings with published literature, and generates reports with visualizations—all without requiring step-by-step guidance from you.
Intelligent data triangulation: BC Catalyst automatically validates findings by pulling evidence from multiple sources simultaneously. The system combines harmonized biomarker data, clinical outcomes, real-world evidence, and external databases to confirm patterns, identify contradictions, and surface supporting evidence—giving you confidence in every insight.
Ultimately, BC Catalyst is about speeding up and improving the way the life sciences can develop breakthrough new therapies and get them to market more efficiently—providing fast, reliable insights for R&D, medical affairs, clinical and commercial teams, and so much more.
Q: How does BC Catalyst help make sense of data?
Keith:BC Catalyst is a prompt-based, AI-native tool that speeds up critical decision-making across life sciences organizations. This means users can simply type in a question and almost immediately receive an answer along with data summaries and visualizations that help identify patient cohorts, uncover potential drug targets, understand genetic variants, and get a clearer view of standards of care, amongst other tasks.
BC Catalyst helps bridge the gap between complex healthcare data and practical, decision-ready intelligence by turning genomic and real-world information into actionable insights across the full drug lifecycle. That gives teams a more complete picture of the precision medicine landscape.
What I find most exciting is that, by bringing together millions of real-world, genomics, and other data points with AI, BC Catalyst allows you to conduct analyses in ways that used to be extremely difficult, time-consuming or expensive.
Q: What does BC Catalyst allow users to do?
Keith: Having a subscription to BC Catalyst gives users the ability to run large-scale data analysis that supports medical innovation. With it, users can:
Build and query patient cohorts quickly using an advanced cohort composer
Use a prompt-based interface that gets straight to the answer you are looking for
Generate downloadable visuals that you can plug into your workflows
Uncover insights into biomarker–drug–response relationships
Explore population-level health trends, real-world outcomes, and shifting standards of care
When you use BC Catalyst, the speed and clarity with which it answers complex questions is amazing – a real game changer!
Q: How can BC Catalyst help life sciences companies?
Keith: BC Catalyst helps close the gap between complex healthcare data and the kind of clear decision-ready intelligence teams need. It delivers insights faster and ensures that every analysis follows the same controlled, reproducible process, which helps business teams, as well clinicians and researchers, trust and reuse the results.
By replacing multiple disconnected tools, reducing reliance on internal IT and data engineering and automating manual workflows, the platform delivers significant cost efficiencies, among other advantages:
Speed up drug development by improving target identification and patient stratification
Strengthen commercial performance by supporting more precise patient-treatment matching
Reduce risk by helping identify potential late-stage issues earlier
Help companies build a competitive edge in the precision medicine space
Q: How does BC Catalyst differ from other advanced analytics products on the market?
Keith: BC Catalyst truly raises the bar for AI- and data-driven healthcare offerings. In my opinion, here’s what sets our platform apart:
It’s one single place where pharma-grade genomics, multi-modal data, public data, and purpose-built agentic AI all come together
A prompt-based interface that lets you search for answers and generate visualizations without extra coding
Support across the full drug lifecycle — from early discovery, to clinical trial acceleration, and through commercial planning and market uptake
A user experience built specifically for pharma teams, bringing together data, compliance, and usability in one environment
Access to integrated datasets from our global network of 150+ partners representing more than 130 million patients in over 25 countries, along with curated public sources that are fully incorporated into the platform
Q: What kinds of use cases can BC Catalyst address?
Keith: BC Catalyst can be used for a wide range of use cases across the drug lifecycle, including:
Drug discovery
Pre-clinical and clinical research
Pre-launch and launch planning
Market access
Post-launch monitoring
It’s designed to help teams work more easily with complex data at each of these stages, so they get clearer insights faster.
Q: What additional BC Catalyst features are planned for release?
Keith: Our team is focused on steadily expanding BC Catalyst’s capabilities across the drug lifecycle. We’re currently focused on specific areas of oncology, but will add more cancer types and broaden the range and geographic reach of the data available next year. We’re also working on an AI-driven report builder and deeper insights into population health and standard of care. There’s much more to come, so stay tuned!
BC Catalyst brings together multi-modal data— including genomic and real-world data and publicly available datasets — and applies generative AI and other machine learning tools that let users ask questions directly. The result is a platform that helps bridge the gap between complex healthcare data and clear, decision-ready intelligence across the drug development cycle. It enables large-scale data analysis that’s faster, repeatable and accessible for business users as well as researchers.
